ProCE Banner Activity

Treatment Considerations for Patients With Essential Thrombocythemia: A Conversation Between Experts

Podcast Episodes

Listen as experts discuss how they tailor current therapeutic options for different patients with essential thrombocythemia.

Released: February 23, 2023

Expiration: February 22, 2024

No longer available for credit.

Share

Faculty

Prithviraj Bose

Prithviraj Bose, MD

Professor
Department of Leukemia
Division of Cancer Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas

Andrew Kuykendall

Andrew Kuykendall, MD

Assistant Member
Department of Malignant Hematology
H. Lee Moffitt Cancer Center
Tampa, Florida

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

GSK

Incyte Corporation

PharmaEssentia Corp

Faculty Disclosure

Primary Author

Prithviraj Bose, MD

Professor
Department of Leukemia
Division of Cancer Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas

Prithviraj Bose, MD: consultant/advisor/speaker: AbbVie, Blueprint, Bristol Myers Squibb, Cogent, CTI, Disc, GlaxoSmithKline, Incyte, Ionis, Jubilant, Karyopharm, Morphic, MorphoSys, Novartis, PharmaEssentia, Sumitomo; researcher: Blueprint, Bristol Myers Squibb, Cogent, CTI, Disc, Geron, Incyte, Ionis, Janssen, Kartos, Karyopharm, MorphoSys, Sumitomo, Telios.

Andrew Kuykendall, MD

Assistant Member
Department of Malignant Hematology
H. Lee Moffitt Cancer Center
Tampa, Florida

Andrew Kuykendall, MD: consultant/advisor/speaker: AbbVie, Blueprint, Bristol-Myers Squibb, CTI Biopharma, Imago, Incyte, MorphoSys, SDP Oncology, Sierra/GlaxoSmithKline.